The Effect of Virtual Reality and Eye Mask During Dressing After CABG Surgery
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorIstanbul University - Cerrahpasa
About this trial
This study aims to evaluate the effects of virtual reality (VR) and eye mask (EM) applications on pain, anxiety, and physiological parameters during dressing after Coronary Artery Bypass Graft (CABG) surgery.
Postoperative dressing procedures, especially after sternotomy, often cause significant pain and anxiety in patients. These issues can negatively impact recovery and increase the need for medication. Non-pharmacological interventions such as VR and EM may help reduce these symptoms.
In this randomized controlled trial, 90 patients are divided into three groups: VR group, EM group, and a control group receiving standard care. Pain and anxiety levels are monitored baseline, immediately after, and 15 minutes after both the first and second dressing procedures. Physiological parameters are measured baseline, during, immediately after, and 15 minutes after both dressing procedures. Additionally, analgesic use is followed baseline and immediately after each dressing procedure. The study is conducted in a cardiovascular intensive care unit in Istanbul, Türkiye. It is expected that the findings will support the integration of VR and EM as effective, low-cost, and non-invasive options for postoperative care, improving patient comfort and healthcare quality.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults aged 18-65 years
First-time coronary artery bypass graft (CABG) surgery for coronary artery disease
ASA physical status I, II, or III
Conscious, oriented, and cooperative
Disqualifiers
Presence of sternal wound infection or inflammation
Intubated at the time of assessment
Undergoing revision surgery
Receiving anesthesia or sedation in the ICU
Trial design
Design model
Parallel
Treatments tested in this trial
Virtual Reality Headset
DeviceDuring the dressing change, nature-themed videos will be shown through a virtual reality headset that immerses the user in a 360-degree, three-dimensional virtual environment.
Eye Mask
DeviceA soft, adjustable, 3D-structured eye mask (Poblex brand) will be applied during the dressing procedure.
Treatment groups
90 Participants
are divided into 3 treatment groupsGroup A: Virtual Reality GroupExperimental treatment 1 intervention
Group B: Eye Mask GroupExperimental treatment 1 intervention
Group C: Control GroupNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Visual Analog Scale (VAS)
Pain intensity will be measured using the Visual Analog Scale (VAS) at three time points: before, immediately after, and 15 minutes after both the first and second sternotomy dressing procedures.
Time frame
Baseline, immediately after, and 15 minutes after first and second dressing2
State-Trait Anxiety Inventory (STAI-II)
State anxiety levels (STAI-I) will be measured before, immediately after, and 15 minutes after both the first and second dressing procedures. Trait anxiety (STAI-II) will be measured only once, before surgery.
Time frame
Baseline, immediately after, and 15 minutes after first and second dressingSecondary outcomes
1
Physiological Parameters (Blood pressure)
Blood pressure will be monitored using a monitor device.
Time frame
Baseline, during, immediately after, and 15 minutes after first and second dressing2
Physiological Parameters (Pulse)
Pulse will be monitored using a monitoring device.
Time frame
Baseline, during, immediately after, and 15 minutes after first and second dressing3
Physiological Parameters (SpO₂)
Saturation values will be monitored using a monitoring device.
Time frame
Baseline, during, immediately after, and 15 minutes after first and second dressing4
Physiological Parameters (Respiratory rate )
Respiratory rate will be monitored using a monitoring device.
Time frame
Baseline, during, immediately after, and 15 minutes after first and second dressingOther outcomes
1
Analgesic Use Frequency
Analgesic agents administered in the intensive care unit, including their names, routes of administration, dosages, and timing, will be systematically documented.
Time frame
Baseline and immediately after first and second dressingSponsors and contacts
Click on the lead sponsor to view all of their trials.
Istanbul University - Cerrahpasa
Lead sponsor
Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Collaborator
Source ClinicalTrials.gov